SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the Sodium-glucose cotransporter-2 (SGLT2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a SGLT2 gene and to methods of treating or preventing a SGLT2-associated disease, such as gout or diabetes, in a subject.
1 . A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of sodium-glucose cotransporter-2 (SGLT2) in a cell,
wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1, and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO: 6, and
wherein the sense strand or the antisense strand is conjugated to one or more lipophilic moieties.
2 . The dsRNA agent of claim 1 , wherein the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences in any one of Tables 2-3.
3 .- 8 . (canceled)
9 . The dsRNA agent of claim 1 , wherein at least one nucleotide comprises a nucleotide modification.
10 . (canceled)
11 . (canceled)
12 . The dsRNA agent of claim 9 , wherein at least one of the nucleotide modifications is selected from the group a deoxy-nucleotide modification, a 3′-terminal deoxythimidine (dT) nucleotide modification, a 2′-O-methyl nucleotide modification, a 2′-fluoro modified nucleotide modification, a 2′-deoxy-nucleotide modification, a 2′-5′-linked ribonucleotide (3′-RNA) modification, a locked nucleotide modification, an unlocked nucleotide modification, a conformationally restricted nucleotide modification, a constrained ethyl nucleotide modification, an abasic nucleotide modification, a 2′-amino-nucleotide modification, a 2′-O-allyl-nucleotide modification, 2′ -C-alkyl-nucleotide modification, a 2′-methoxyethyl nucleotide modification, a 2′-O-alkyl-nucleotide modification, a morpholino nucleotide modification, a phosphoramidate modification, a non-natural base comprising nucleotide modification, a tetrahydropyran nucleotide modification, a 1,5-anhydrohexitol nucleotide modification, a cyclohexenyl nucleotide modification, a nucleotide comprising a 5′-phosphorothioate group modification, a nucleotide comprising a 5′-methylphosphonate group modification, a nucleotide comprising a 5′ phosphate or 5′ phosphate mimic modification, a nucleotide comprising vinyl phosphonate modification, a glycol nucleic acid (GNA) modification, a glycol nucleic acid S-Isomer (S-GNA) modification, a nucleotide comprising 2-hydroxymethyl-tetrahydrofuran-5-phosphate modification, a nucleotide comprising 2′-deoxythymidine-3′phosphate modification, a nucleotide comprising 2′-deoxyguanosine-3′-phosphate modification, and a terminal nucleotide linked to a cholesteryl derivative and a dodecanoic acid bisdecylamide group modification; and combinations thereof.
13 .- 15 . (canceled)
16 . The dsRNA agent of claim 12 , further comprising at least one phosphorothioate internucleotide linkage.
17 . (canceled)
18 . The dsRNA agent of claim 1 , wherein cach strand is independently no more than 30 nucleotides in length.
19 . The dsRNA agent of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide.
20 .- 29 . (canceled)
30 . The dsRNA agent of claim 1 , wherein one or more lipophilic moieties are conjugated to one or more internal positions on at least one strand.
31 .- 39 . (canceled)
40 . The dsRNA agent of claim 1 , wherein the one or more lipophilic moieties are conjugated to one or more of the internal positions selected from the group consisting of positions 4-8 and 13-18 on the sense strand, and positions 6-10 and 15-18 on the antisense strand, counting from the 5′-end of each strand.
41 .- 50 . (canceled)
51 . The dsRNA agent of claim 1 , wherein the lipophilic moiety contains a saturated or unsaturated C6-C18 hydrocarbon chain.
52 . (canceled)
53 . (canceled)
54 . The dsRNA agent of claim 1 , wherein the lipophilic moiety is conjugated via a carrier that replaces one or more nucleotide(s) in the internal position(s) or the double stranded region.
55 . (canceled)
56 . (canceled)
57 . The dsRNA agent of claim 1 , wherein the lipophilic moiety is conjugated to a nucleobase, sugar moiety, or internucleosidic linkage.
58 .- 66 . (canceled)
67 . The dsRNA agent of claim 1 , further comprising a phosphate or phosphate mimic at the 5′-end of the antisense strand.
68 .- 70 . (canceled)
71 . A cell containing the dsRNA agent of claim 1 .
72 . A pharmaceutical composition for inhibiting expression of a SGLT2 gene, comprising the dsRNA agent of claim 1 .
73 . (canceled)
74 . A method of inhibiting expression of a SGLT2 gene in a cell, the method comprising:
(a) contacting the cell with the dsRNA agent of claim 1 ; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the SGLT2 gene, thereby inhibiting expression of the SGLT2 gene in the cell.
75 .- 77 . (canceled)
78 . A method of treating a subject having a disorder that would benefit from reduction in sodium-glucose cotransporter-2 (SGLT2) expression, comprising administering to the subject a therapeutically effective amount of the dsRNA agent of claim 1 , thereby treating the subject having the disorder that would benefit from reduction in SGLT2 expression.
79 . (canceled)
80 . The method of claim 78 , wherein the disorder is a SGLT2-associated disorder.
81 . The method of claim 80 , wherein the SGLT2 -associated disorder is gout; or diabetes.
82 .- 93 . (canceled)
94 . A kit, a vial, or a syringe comprising the dsRNA agent of any one of claim 1 .
95 .- 97 . (canceled)